Kymera IPO Presentation Deck

* Mice carrying MYD-88 mutated OCI-Ly10 xenografts treated with daily IRAKIMID doses (5 and 25 mg/kg) Tumor Regressions from Substantial Degradation of IRAK4 and IMID Substrates in Preclinical Xenograft Model • Dose-dependent degradation of IRAK4, Ikaros/Aiolos observed, and more than 80% degradation associated with onset of regression # Data support hypothesis that superior single-agent anti-tumor activity driven by downregulation of both MYD88 and IRF4 pathways KYMERA Tumor Volume (mm³) 1500 1000 500 0 Vehicle, QD x 21 days IRAKMID 5 mg/kg, QD x 21 days IRAKMID 25 mg/kg, QD x 21 days 7 Days 21 28 100 8 Target Degradation (% Control) 80 40 IRAK4 Ikaros Aiolos 5 25 IRAKIMID Degrader Dose (mg/kg)

View entire presentation